Figure 6

Molecular profiles of PTEN-deficient prostate cancer after combination therapy with sorafenib and everolimus. (A) Expression of AR, GAPDH, and phosphorylated and total proteins of AKT, GSK3β, β-catenin, mTOR, S6, 4E-BP1, EIF-4B, ERK1/2 and STAT3 in prostate tumor lysates from mice with CNPC and CRPC after the indicated treatments. Densitometric analysis of (A) in CNPC (B) and CRPC (C) intervention models. GAPDH was used as a loading control. Relative protein expression levels were normalized to GAPDH for AR or corresponding total protein for phosphorylated proteins. Plots are expressed as the mean ± s.e. relative to control.